Merck Announces Management Changes
Merck promotes internal managers to head Merck Millipore and Consumer Health Divisions.
Merck KGaA
reported the promotion of three internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit as part of its “Fit for 2018” program.
Udit Batra, who previously managed Consumer Health, will become president and CEO of the Life Science Tools division, succeeding Robert Yates, who has left the company. Uta Kemmerich-Keil, currently CEO of Allergopharma and head of the global allergy business unit, will succeed Batra in his role as president and CEO of Consumer Health. Kemmerich-Keil will be replaced at Allergopharma by Marco Linari, who was head of the Operating Model within Merck Millipore and Performance Materials. All changes will take effect May 15.
In addition, Merck Serono President and CEO Belén Garijo will take charge of the R&D organization ad interim while the search for a permanent leader for the R&D organization is conducted. Annalisa Jenkins, who served in that role, left the company at the end of March.
Source:
Merck KGaA
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
